Please note: This is for information only.

Refer to local guidelines for treatment recommendations




  • A lincosamide antibiotic.
  • No dosage adjustment necessary in renal impairment
  • Adjust dose in hepatic impairment
  • Avoid co-administration with erythromycin or neuromuscular blocking agents.
  • Very good bioavailability when given orally
  • Good penetration into tissue and bone.
  • High risk of Clostridium difficile antibiotic-associated diarrhoea if prescribed for elderly inpatients.

Main indications:

  • Serious streptococcal infections (eg: cellulitis), in combination with or as an alternative to benzylpenicillin.
  • Second line agent for serious soft tissue infections due to S aureus
  • Alternative to metronidazole for anaerobic infections.

Active against most strains of:

  • Haemolytic streptococci
  • Staphylococcus aureus – including some MRSA
  • Anaerobes

Not active against most strains of:

  • Enterococcus
  • Eschericia coli
  • Coliforms
  • Pseudomonas aeruginosa